Discovery and development of biopharmaceuticals: current issues
- 1 December 2009
- journal article
- editorial
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 20 (6) , 668-672
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Optimization of Fc-mediated effector functions of monoclonal antibodiesCurrent Opinion in Biotechnology, 2009
- Brand biologics grab 12 years' exclusivity, for nowNature Biotechnology, 2009
- Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studiesRegulatory Toxicology and Pharmacology, 2009
- Biosimilar therapeutics--what do we need to consider?NDT Plus, 2009
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- Biosimilars: it’s not as simple as cost aloneJournal of Clinical Pharmacy and Therapeutics, 2008
- Protein therapeutics: a summary and pharmacological classificationNature Reviews Drug Discovery, 2008
- The challenge of biosimilarsAnnals of Oncology, 2007
- Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and BeyondHematology-American Society Hematology Education Program, 2007
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003